Esketamine nasal spray (Spravato®) is approved in the US for the indication “treatment-resistant depression.” On another page on this website, I discussed what “treatment-resistant depression” meant in clinical trials of esketamine nasal spray along with an antidepressant for the treatment of “treatment-resistant depression.” I concluded that based on the Inclusion criteria and Baseline characteristics, the…